Luminous Therapeutics is an early startup focusing on genetic medicine and infectious diseases with advanced scientific technology and located in Maryland about 20 min away from US FDA main campus.
Luminous mission is to develop saRNA-based vaccines for emerging and re-emerging infectious diseases and to provide at an “Operation-Warp Speed” and at low cost to US and to low to middle income countries (LMIC) throughout the world. Our platform technology is flexible and a plug-and-play cassette technology that canbe used to produce a range of different target antigens.
Our saRNA vaccine platform has higher manufacturing productivity and lower cost per dose compared to mRNA vaccines. The self-replicating strategy has the advantage of achieving longer-term antigen expression and a much higher level of antigen expression at lower mRNA
OUR TEAM
We have an industry leading management team and senior advisors with significant experience in emerging and re-emerging infectious diseases, immunology and rare disease.
Our PI has over 30 years of experience in infectious diseases and vaccine discovery as well as animal models for assessing delivery, immunogenicity, and challenge models.
Our technology development PI’s have extensive experience and knowledge related to LNP formulations and targeted delivery of saRNA.
Our CMC team has broad experience in cGMP manufacturing of vaccines that have been used in human phase 1, 2 and 3 clinical trials and Commercial Productions in United States, Europe, and Australia.